Form 4: Marinus Pharmaceuticals Director Fischer Sells Shares and Options in Merger with Immedica Pharma AB

Director Seth H. Z. Fischer reports the sale of Marinus Pharmaceuticals shares and termination of stock options following the merger agreement with Immedica Pharma AB.

Summary

• Seth H. Z. Fischer, a director of Marinus Pharmaceuticals, reported changes in beneficial ownership following the company's merger agreement with Immedica Pharma AB.
• On February 7, 2025, Fischer disposed of 12,707 shares of common stock at $0.55 per share due to the merger agreement.
• Fischer also disposed of 2,300 shares underlying Restricted Stock Units (RSUs), which were terminated for a cash payment based on the offer price of $0.55 per share.
• On February 11, 2025, Fischer disposed of various out-of-the-money stock options, which were terminated without any payment as per the merger agreement terms.
• The reported amount of previously held common stock was adjusted to correct a clerical error, increasing the holdings by 2,081 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions related to a merger agreement, without expressing positive or negative views.

Negatives

• Fischer's stock options were terminated without any payment, indicating they were out-of-the-money at the time of the merger.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger agreement.

Industry Context

This announcement reflects a merger and acquisition activity within the pharmaceutical industry, where companies are often acquired to expand product portfolios or gain access to new markets.

Stakeholder Impact

• Shareholders received $0.55 per share as part of the merger agreement.
• Employees may experience changes as a result of the merger.

Key Dates

Keywords

Marinus Pharmaceuticals, Immedica Pharma AB, Merger, Beneficial Ownership, Stock Options, Restricted Stock Units, Form 4, Director, Fischer, MRNS